CDK10 Antibody

What is CDK10 and what are its key biological functions?

CDK10, also known as serine/threonine-protein kinase PISSLRE, is a member of the cyclin-dependent kinase family with important functions beyond traditional cell cycle control. CDK10 is activated through complex formation with Cyclin M, and this complex mediates degradation of the transcription factor ETS2 . Unlike classical cell cycle CDKs, CDK10 participates in multiple cellular processes including transcriptional regulation and signal transduction. Research has identified CDK10 as a potential tumor suppressor in several cancer types, including nasopharyngeal carcinoma and gastric cancer . Loss of CDK10 appears to be a major determinant of resistance to endocrine therapy for breast cancer . Additionally, CDK10 plays important roles during development, as demonstrated in zebrafish models where it participates in transcriptional complexes essential for nervous system development .

What types of CDK10 antibodies are available for research applications?

Several types of CDK10 antibodies are available for research purposes, each optimized for specific applications:

When selecting a CDK10 antibody, researchers should consider:

• The specific application (WB, IHC, IF, etc.)

• Target species reactivity (human, mouse, rat, etc.)

• Epitope location relative to functional domains

• Validation data provided by manufacturers

• Whether the antibody recognizes specific post-translational modifications

What is the molecular weight and subcellular localization of CDK10?

CDK10 typically appears as a band of approximately 38-40 kDa on Western blots, though this can vary slightly depending on post-translational modifications and experimental conditions . Some antibodies detect CDK10 at 43 kDa, likely representing a different isoform or modified version of the protein .

Regarding subcellular localization, immunohistochemistry studies have shown that CDK10 is predominantly localized in the cytoplasm of cells, though it may translocate under specific conditions. In gastric cancer tissues, positive CDK10 expression was observed in the cytoplasm in 51.3% of tumor samples versus reduced expression in 48.7% of cases . The cytoplasmic localization is consistent with CDK10's role in signaling pathways and protein degradation mechanisms rather than direct DNA binding.

How should CDK10 antibodies be optimized for Western blotting applications?

For optimal Western blot detection of CDK10, consider the following protocol recommendations:

Sample preparation:

• Use RIPA or NP-40 based lysis buffers with protease inhibitors

• Include phosphatase inhibitors if studying phosphorylation states

• Typical loading amount: 20-50 μg total protein per lane, though this may need to be increased for low-expressing samples

Electrophoresis conditions:

• 10-12% SDS-PAGE gels provide good resolution for the 38-40 kDa CDK10 protein

• Include molecular weight markers to confirm correct band identification

Antibody conditions:

• Primary antibody dilution: typically 1:1000 (though this varies by antibody)

• Overnight incubation at 4°C generally provides optimal results

• Secondary antibody selection should match the host species of the primary antibody

Controls:

• Positive controls: Cell lines known to express CDK10 (e.g., 293 cells )

• Negative controls: CDK10 knockdown or knockout cells

• Loading controls: β-actin, GAPDH, or total protein staining

Troubleshooting multiple bands:

• 38-40 kDa is the expected size for CDK10

• Additional bands may represent alternative splice variants, degradation products, or non-specific binding

• Peptide competition assays can help confirm band specificity

What are the optimal conditions for CDK10 immunohistochemistry?

Successful CDK10 immunohistochemistry requires careful optimization of several parameters:

Tissue preparation and fixation:

• 10% neutral buffered formalin fixation for 24-48 hours is standard

• Paraffin embedding and sectioning at 4-5 μm thickness

Antigen retrieval:

• Heat-induced epitope retrieval using citrate buffer (pH 6.0) is effective for most CDK10 antibodies

• Microwave or pressure cooker methods (15 minutes) provide consistent results

Antibody incubation:

• Primary antibody dilutions vary by product (e.g., 1:500 for some antibodies)

• Overnight incubation at 4°C typically provides optimal staining

• HRP-conjugated secondary antibodies followed by DAB development is standard

Scoring systems:

• Percentage of positive cells: 0 (0-9%), 1 (10-25%), 2 (26-50%), 3 (51-100%)

• Staining intensity: 0 (no staining), 1 (weak), 2 (moderate), 3 (strong)

• Total immunostaining score = percentage score × intensity score (range 0-9)

Controls:

• Positive control tissues with known CDK10 expression

• Negative controls (primary antibody omission)

• Internal positive controls within tissue sections when possible

How can CDK10 expression be accurately quantified in clinical samples?

Accurate quantification of CDK10 expression in clinical samples requires standardized methodologies:

For Western blot quantification:

• Use densitometry software (ImageJ, Image Lab, etc.)

• Normalize to loading controls or total protein

• Include standard curves when possible

• Compare relative expression between samples rather than absolute values

For immunohistochemistry quantification:

• Semi-quantitative scoring systems as described above

• Multiple independent observers to reduce subjective bias

• Digital image analysis using specialized software for objective assessment

For mRNA expression analysis:

• qRT-PCR with validated primers and appropriate reference genes

• Normalize to multiple housekeeping genes for accuracy

• Follow MIQE guidelines for qPCR experiments

Multi-method validation:

• Compare protein expression (IHC/WB) with mRNA levels (qRT-PCR)

• Use multiple antibodies targeting different epitopes when possible

• Consider mass spectrometry for absolute quantification

In the study by You et al., CDK10 expression was significantly reduced in 92 of 189 (48.7%) gastric cancer cases compared to normal tissue, and this reduction correlated with worse prognosis . This highlights the importance of standardized quantification approaches in clinical studies.

How can I investigate the CDK10/Cyclin M complex and its functions?

Studying the CDK10/Cyclin M complex requires specialized approaches:

Co-immunoprecipitation methods:

• Use mild lysis buffers to preserve protein-protein interactions

• Immunoprecipitate with either CDK10 or Cyclin M antibodies

• Perform reciprocal IP (pull down with one antibody, detect with the other)

• Include phosphatase inhibitors to preserve phosphorylation-dependent interactions

Functional studies:

• Kinase activity assays using recombinant CDK10/Cyclin M complexes

• Known substrates include RNA polymerase II CTD, c-MYC, and ETS2

• Radioactive assays with [γ-32P]ATP provide sensitive detection of activity

Interaction mapping:

• Domain deletion mutants to identify interaction regions

• Proximity ligation assays for in situ detection of the complex

• Mass spectrometry to identify additional complex components

ETS2 degradation assays:

• Monitor ETS2 levels after manipulating CDK10/Cyclin M expression

• Use proteasome inhibitors to confirm degradation mechanism

• Examine downstream effects on ETS2 target genes

Research has shown that the CDK10/Cyclin M complex mediates degradation of the transcription factor ETS2, which affects expression of genes including c-RAF and matrix metalloproteinases (MMP2/9) .

What approaches are effective for studying CDK10's role in cancer?

Investigating CDK10's tumor suppressor functions requires multiple complementary approaches:

Expression analysis in cancer samples:

• Compare CDK10 levels in matched tumor/normal tissues

• Correlate expression with clinical parameters and outcomes

• Multiple studies have shown reduced CDK10 expression in various cancers including gastric cancer and lung adenocarcinoma

In vitro functional studies:

• Knockdown or overexpression of CDK10 in cancer cell lines

• Assess effects on:

  • Cell proliferation and cell cycle progression

  • Migration and invasion capabilities

  • Apoptosis and chemosensitivity

  • EMT marker expression

Pathway analysis:

• Examine effects on MAPK pathway components (c-Raf/MEK/ERK)

• Monitor ETS2 levels and activity

• Evaluate MMP2/9 expression and activity

In vivo models:

• Xenograft models with CDK10 manipulation

• Patient-derived xenografts for translational relevance

• Metastasis models to assess CDK10's role in cancer progression

Findings from a colorectal cancer study demonstrated that CDK10 promotes tumor growth while inhibiting apoptosis by upregulating Bcl-2 expression . Importantly, this effect depends on its kinase activity, as kinase-defective mutants showed increased apoptosis and reduced proliferation . In a lung adenocarcinoma study, CDK10 was found to suppress metastasis by promoting ETS2 degradation, thereby inactivating the c-Raf/MEK/ERK pathway that drives epithelial-mesenchymal transition .

What inhibitors are available for CDK10 and how specific are they?

The development of selective CDK10 inhibitors has been challenging due to the high homology between CDK family members. Current knowledge about CDK10 inhibitors includes:

Cross-reactivity with other CDKs:

• Several CDK inhibitors show activity against CDK10 but typically with less potency than against their primary targets

• OTS964 (a CDK11 inhibitor) showed only moderate activity against CDK10 (IC₅₀ of 5.37 μM) but was more selective compared to other tested compounds

Specificity considerations:

• FDA-approved CDK4/6 inhibitors (abemaciclib, palbociclib) show minimal cross-reactivity with CDK10

• Covalent CDK7/12/13 inhibitors (THZ-1, YKL-5-124, THZ-531) also have limited effect on CDK10

Experimental approaches:

• In vitro kinase assays using purified CDK10/Cyclin Q complexes provide the most direct assessment of inhibitor efficacy

• Cellular assays must consider pathway redundancy and compensatory mechanisms

• Genetic approaches (CRISPR, shRNA) offer more selective CDK10 inhibition for research purposes

For therapeutic targeting, understanding the structural determinants of CDK10 binding specificity will be crucial for developing selective inhibitors.

What are common technical challenges when working with CDK10 antibodies?

Researchers may encounter several challenges when using CDK10 antibodies:

Non-specific banding patterns:

• Multiple bands on Western blots may represent:

  • Alternative splice variants of CDK10

  • Post-translational modifications

  • Cross-reactivity with other CDK family members

  • Non-specific binding

• Validation strategies include using CDK10 knockdown/knockout samples and peptide competition assays

Weak or variable signal:

• For Western blots: optimize protein extraction, increase loading amount, try longer exposure times

• For IHC: optimize antigen retrieval, extend primary antibody incubation, consider signal amplification systems

Inconsistent results between antibodies:

• Different antibodies target distinct epitopes which may be differentially accessible

• Compare antibodies targeting different regions of CDK10

• Document exact conditions that work for each antibody

Background issues:

• Optimize blocking conditions (concentration, time, blocking agent)

• Increase wash steps in duration and number

• Consider using more dilute antibody with longer incubation times

How can I validate the specificity of a CDK10 antibody?

Proper validation is essential for ensuring reliable results with CDK10 antibodies:

Genetic validation:

• Test antibody in CDK10 knockout or knockdown models

• Compare with CDK10 overexpression samples

• Use multiple siRNA/shRNA constructs targeting different regions

Peptide competition:

• Pre-incubate antibody with immunizing peptide

• Specific signal should be abolished while non-specific binding remains

Cross-platform verification:

• Compare protein detection by Western blot, IHC, and IF

• Correlate with mRNA expression by qRT-PCR or RNA-seq

• Consider mass spectrometry for definitive protein identification

Comparative antibody testing:

• Use multiple antibodies targeting different epitopes

• Compare monoclonal vs. polyclonal antibodies

• Test antibodies from different manufacturers

What considerations are important when studying CDK10 in different species?

When using CDK10 antibodies across different species, several factors should be considered:

Sequence homology:

• Human CDK10 shares high sequence conservation with mouse and rat orthologs

• Critical epitopes may vary between species, affecting antibody binding

• Consider sequence alignment of the antibody epitope across species

Validated reactivity:

• Most commercial CDK10 antibodies have been validated for human, mouse, and rat

• Predicted reactivity has been suggested for additional species including pig, zebrafish, bovine, horse, sheep, dog, chicken, and Xenopus

• Experimental validation is required before relying on predicted cross-reactivity

Model selection:

• Consider using genetic models (knockouts, knock-ins) to validate antibody specificity in non-human systems

• For developmental studies, zebrafish models have been successfully used to study CDK10 function

• Xenograft models with human cell lines provide an alternative to directly studying CDK10 in animal tissues

Application-specific optimization:

• Fixation and processing protocols may need species-specific adjustments

• Antigen retrieval conditions often require optimization for each species

• Positive control tissues from the target species should be included

How does CDK10 expression correlate with cancer prognosis?

Multiple studies have investigated the relationship between CDK10 expression and cancer outcomes:

Gastric cancer:

Colorectal cancer:

Lung adenocarcinoma:

Breast cancer:

• Loss of CDK10 expression appears to be a major determinant of resistance to endocrine therapy

• CDK10 regulates expression of c-RAF and signaling through the MAPK pathway

These findings suggest that CDK10 may serve as a valuable prognostic marker in multiple cancer types, though its role (tumor suppressor vs. oncogenic) may be context-dependent.

What are the key methodological considerations for CDK10 immunohistochemistry in cancer diagnosis?

For clinical applications of CDK10 immunohistochemistry, several methodological factors are critical:

Sample processing standardization:

• Consistent fixation protocols (10% neutral buffered formalin for 24-48 hours)

• Standard tissue processing and embedding procedures

• Validation on tissue microarrays for high-throughput analysis

Staining protocol:

• Validated antibody selection with documented specificity

• Optimized antigen retrieval (citrate buffer pH 6.0) as used in prognostic studies

• Standardized detection systems (e.g., HRP/DAB)

• Inclusion of positive and negative controls in each batch

Scoring system:

• Combination of percentage of positive cells and staining intensity

• Total immunostaining score calculation: percentage score × intensity score (0-9)

• Classification into negative (score 0), weakly positive (1-3), positive (4-6), or strongly positive (7-9)

• Multiple independent pathologists for scoring to minimize subjectivity

Clinical correlation:

• Comprehensive clinical data collection (stage, treatment, outcome)

• Appropriate statistical analysis (Kaplan-Meier, Cox regression)

• Multivariate analysis to adjust for confounding factors

In the gastric cancer study by You et al., this methodological approach successfully identified CDK10 as an independent prognostic factor (P=0.011) in multivariate Cox regression analysis .